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Abstract
Background: β-lactamase conjugated with environment-sensitive fluorescein molecule to residue 166 on the
Ω-loop near its catalytic site is a highly effective biosensor for β-lactam antibiotics. Yet the molecular mechanism of
such fluorescence-based biosensing is not well understood.
Results: Here we report the crystal structure of a Class A β-lactamase PenP from Bacillus licheniformis 749/C with
fluorescein conjugated at residue 166 after E166C mutation, both in apo form (PenP-E166Cf) and in covalent
complex form with cefotaxime (PenP-E166Cf-cefotaxime), to illustrate its biosensing mechanism. In the apo
structure the fluorescein molecule partially occupies the antibiotic binding site and is highly dynamic. In the PenP-
E166Cf-cefatoxime complex structure the binding and subsequent acylation of cefotaxime to PenP displaces
fluorescein from its original location to avoid steric clash. Such displacement causes the well-folded Ω-loop to
become fully flexible and the conjugated fluorescein molecule to relocate to a more solvent exposed environment,
hence enhancing its fluorescence emission. Furthermore, the fully flexible Ω-loop enables the narrow-spectrum
PenP enzyme to bind cefotaxime in a mode that resembles the extended-spectrum β-lactamase.
Conclusions: Our structural studies indicate the biosensing mechanism of a fluorescein-labelled β-lactamase. Such
findings confirm our previous proposal based on molecular modelling and provide useful information for the
rational design of β-lactamase-based biosensor to detect the wide spectrum of β-lactam antibiotics. The
observation of increased Ω-loop flexibility upon conjugation of fluorophore may have the potential to serve as a
screening tool for novel β-lactamase inhibitors that target the Ω-loop and not the active site.
Background
β-Lactamase is one of the major mechanisms of antibio-
tic resistance in bacteria. Enzymes of this family deacti-
vate β-lactam antibiotics by hydrolyzing the conserved
β-lactam moiety in the antibiotics and rendering them
ineffective to bind to their target proteins, the penicillin-
binding proteins (PBPs), which are essential for bacterial
cell wall synthesis and survival [1,2]. Detailed mechanis-
tic studies of these enzymes over the past decades have
revealed a conserved mechanism of β-lactam hydrolysis
that consists of two steps, the acylation step in which
the β-lactam ring is “opened” and acylated to the side
chain hydroxyl group of Ser70 through nucleophilic
attack to form the enzyme-substrate acyl adduct ES*;
followed by the deacylation step in which the ES* inter-
mediate is hydrolyzed and released as E + P facilitated
by Glu166 (residue numbering according to the most
conserved Class A β-lactamases) [3].
The substrate profile of a β-lactamase in hydrolyzing
diverse β-lactam antibiotics is strongly influenced by a
structural element termed Ω-loop, a short stretch of
residues on the surface of the β-lactamase structure that
forms part of the outer part of the antibiotic binding
site [4-9]. For narrow-spectrum β-lactamases such as
the PenP used in this study and the clinically significant
TEM-1 or SHV-1 enzymes, Ω-loop is tightly packed
onto the enzyme active site through hydrophobic and
electrostatic interactions with residues lining the
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catalytic site, posing as steric hindrance for binding of
second- or third-generation antibiotics with bulky side
chains attached onto the β-lactam nucleus. Many
mutant strains of TEM- and SHV-like β-lactamases
overcome this inefficiency and broaden their hydrolytic
profile by acquiring mutations in the Ω-loop region to
render this region more flexible to accommodate large-
sized antibiotics [4-10]. Many extended-spectrum
β-lactamases have significantly extended Ω-loop, result-
ing in an enlarged active site that readily binds to and
hydrolyzes almost all antibiotics [11-13].
Exploiting the proximity of Ω-loop to the antibiotic
binding site and its structural flexibility, we have suc-
cessfully converted a β-lactamase PenPC from Bacillus
cereus 569/H into a biosensor for β-lactam antibiotics
by mutating the catalytically critical residue Glu166 on
the Ω-loop to cysteine and conjugating an environment-
sensitive fluorescein molecule to its reactive side chain
thiol group to form PenPC-E166Cf as reported in pre-
vious studies [14-16]. Fluorescein is an environment-
sensitive fluorophore with suppressed fluorescence in a
hydrophobic environment but fluoresces strongly in a
polar aqueous environment [17]. The mutation of
Glu166 to cysteine severely reduces the efficiency of the
deacylation step of β-lactamase catalysis, rendering the
enzyme to stall at the acylation step and form a stable
ES* acyl adduct that enhances the fluorescence emission
of the conjugated fluorescein [16]. We have speculated
that the fluorescein molecule is positioned near the cat-
alytic site so that the binding and subsequent acylation
of β-lactam antibiotics would displace it to a more polar
environment, enhancing its fluorescence intensity [16].
Here we report structural studies of fluorescein-
conjugated PenP β-lactamase from Bacillus licheniformis
749/C to validate our proposed biosensing mechanism.
The structural findings suggest an important role of Ω-
loop in the biosensing process, which will help the
rational design of improved biosensors for β-lactam
detection as well as for novel antibiotics discovery.
Results and Discussion
The biosensing profile of PenP-E166Cf
The biosensing profile of fluorescein conjugated PenP
(PenP-E166Cf) for detecting β-lactam antibiotics have
never been reported before. In our previous study, a
highly similar enzyme, PenPC from Bacillus cereus 569/
H with 58% amino acid sequence identity to PenP, was
successfully engineered into a biosensor using the same
design scheme (PenPC-E166Cf) [15,16]. We chose to
work with PenP in this study for the advantage of its
easy propensity for crystallization, which would enable
structural studies to understand its biosensing mechan-
ism at atomic resolution. PenPC, on the other hand, has
poor thermal stability and is difficult to crystallize.
Because of the high sequence similarity between these
two proteins, as well as the general sequence conserva-
tion among all Class A β-lactamase enzymes we expect
that PenP can serve as a good model system to under-
stand the biosensing mechanism of fluorescein-based
biosensing.
Indeed the biosensing profile of PenP-E166Cf is highly
similar to that of PenPC-E166Cf. The conjugation of
fluorescein to the mutated Cys166 residue through thiol
linkage is highly efficient for PenP. The ESI-MS profile
confirmed that over 90% of PenP was labelled by the
fluorophore and converted to PenP-E166Cf, with little
unlabelled PenP remaining (Figure 1a). The fluorescence
scanning spectrum of PenP-E166Cf shows an increase of
~25% in emitted intensity when the antibiotic cefotaxime
is present at 10 μM concentration (Figure 1b). A variety
of β-lactam antibiotics, including the first-, second- and
third-generation compounds with diverse chemical struc-
tures in addition to the conserved β-lactam core, induce
significant fluorescence enhancement in PenP-E166Cf at
concentration as low as 1 μM (Figure 1c). Lastly the
time-dependent spectra of PenP-E166Cf in the presence
of cefotaxime at different concentrations ranging from
0.01 μM to 10 μM shows that PenP-E166Cf can detect
cefotaxime at concentration as low as 0.01 μM and the
fluorescence response is saturated at 1 μM (Figure 1d).
The structure of PenP-E166Cf in apo form
PenP-E166Cf readily crystallized in the form of clustered
needles. These crystals were tinted in bright yellow col-
our, indicating the presence of fluorescein (data not
shown YZ). To confirm that fluorescein remaining con-
jugated to the protein in the crystal form we harvested
and thoroughly washed these yellow-coloured crystals
and analyzed the dissolved crystals on SDS-PAGE gel
under both visible and UV light. A band corresponding
to PenP (~30.5 kDa) is clearly visible under both condi-
tions, confirming that the crystals are indeed of PenP-
E166Cf (data not shown YZ).
The structure of PenP-E166Cf was solved by molecu-
lar replacement using the known structure of PenP
(PDB ID 4BLM) as search model. Two molecules of
PenP-E166Cf are found in each asymmetric unit. Struc-
ture rebuilding and refinement were done in CCP4 pro-
gram [18]. The overall structure of PenP-E166Cf is
largely identical to that of the wild-type unlabeled PenP.
The RMSD of all 4011 protein atoms between the
labeled and wild-type structures is just ~1.5 Å. For main
chain atoms, the RMSD is only 0.8 Å. Key residues lin-
ing the catalytic site, including Ser70 and mutated
Cys166 are virtually identical between the labeled and
wild-type structures (Figure 2a). In summary the conju-
gation of fluorescein to PenP does not alter its overall
structural folding.
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The fluorescein molecule was modeled onto the PenP
structure after careful inspection of the fo-fc and 2fo-fc
electron density map. These maps are not of high qual-
ity at regions around the fluorescein conjugation site,
with only pieces of discontinuous density visible at 2.0 s
contour level in the fo-fc map (Figure 2a). We tried our
best to fit fluorescein into these pieces of electron den-
sity, particularly matching the melaimide group to a
piece of electron density near the thiol side chain of
Cys166, as well as matching the xanthene group at the
end of the fluorescein molecule to a large piece of elec-
tron density near the catalytic site (Figure 2a). This
modeled structure is stable after rounds of structural
refinement, showing good electron density for the
Ω-loop residues and the fluorescein molecule at 1.0 s
contour level in the 2fo-fc map, suggesting that our
fitting is reasonable (Figure 2b). However, no electron
density was visible for the benzoic group in the
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Figure 1 Biosensing of b-lactam antibiotics by fluorescein-labelled PenP. (a) De-convoluted ESI mass spectrum of PenP-E166Cf. The add-up
at the bottom confirms the correct mass of the labelled protein. (b) Fluorescence scanning spectra of PenP-E166Cf in the presence of 10-5M
cefotaxime in 50 mM phosphate buffer (pH 7.0). (c) Change in fluorescence emission of PenP-E166Cf after incubation with different antibiotics
(cefotaxime, ceftriaxone, ceftazidime, cephaloridine, cephalothin, cefoxitin, cefuroxime, penicillin G and ampicillin) at 10-6 M for 100 s. (d) Time-
dependent fluorescence spectra in the presence of different concentrations (1 × 10-8 M - 1 × 10-5 M) of cefotaxime monitored at 515 nm.
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mid-region of the fluorophore molecule, indicating that
this region is more disordered as compared to other
parts of the fluorophore molecule.
In our PenP-E166Cf structure the fluorescein molecule
partially occupies the outer edge of the antibiotic binding
region and is in close contact with several residues at the
catalytic site. The maleimide moiety near the thiol link-
age site is inserted into the catalytic core, located within
2.5 Å from the side chain of Ser70 on one side and 3.5 Å
away from Ω-loop on the other side. The xanthene group
near the other end of the fluorescein molecule extends
toward the solvent (Figure 2b), loosely packed against
β-strand B3 that forms part of the extended substrate
binding area involved in coordinating antibiotics as
shown in the extended-spectrum class A β-lactamase,
Toho-1, in complex with cefotaxime, cephalothin, and
benzylpenicillin [19]. No specific interactions were
observed between fluorescein and the protein. Total sol-
vent accessible area is 188 Å2, 33% of the total surface
area, indicating that fluorescein is partially packed against
the PenP molecule and not fully solvent exposed. The
fluorescein molecule is highly dynamic, as reflected by
the poor electron density map as well as high average
temperature factor (~72.3). In contrast, the rest of the
structure shows excellent electron density and low aver-
age temperature factor (~23.5) that is typical of the 2.2 Å
data set. The Ω-loop, on which the fluorescein molecule
is conjugated, was little affected by the dynamic fluoro-
phore and adopts the same conformation as that of the
unlabelled PenP (Figure 2b).
The structure of PenP-E166Cf in complex with cefotaxime
We chose to determine the PenP-E166Cf-cefotaxime
structure, using cefotaxime as a representative of the
many β-lactam antibiotics because of its positive fluores-
cence response induced in PenP-E166Cf as well as its
chemical structure that contains functional groups typi-
cal of both second- and third-generation antibiotics.
Cefotaxime was soaked into the PenP-E166Cf crystals
by incubating the crystals in the reservoir solution with
0.01 M cefotaxime added for 20 minutes. The PenP-
E166C structure, without the conjugated fluorescein
molecule, was used as the starting model for structure
determination. After initial rounds of refinement both
the fo-fc and 2fo-fc electron density maps were carefully
inspected for evidence of cefotaxime and fluorescein, as
well as for any structural changes on PenP.
The cefotaxime was clearly visible in fo-fc electron
density map as covalently bonded through its carbonyl
carbon atom C7 to the Og atom of Ser70, which repre-
sents the acylated ES* adduct (Figure 3a). But we could
not identify any electron density in either fo-fc or 2fo-fc
?-loop
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Ser70
Cys166
2.5 Å
(b)
Ser70
Cys166
?-loop
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Figure 2 Crystal structure of PenP-E166Cf. (a) The fo-fc omit map of fluorescein-5-maleimide contoured at 2.0 s. (b) The 2fo-fc map of
Phe165 to Asn170 and fluorescein-5-maleimide contoured at 1.0 s. Side chains of Phe165 to Asn170 and Ser70 are shown in cpk cylinder
model. Fluorescein is shown in green cylinder model.
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map that would be accountable for fluorescein molecule
around the location seen in PenP-E166Cf or anywhere
nearby. Furthermore, the fo-fc map showed strong nega-
tive signal for a large segment of Ω-loop (residues 164
to 174) and the 2fo-fc map showed no electron density
for this region at all, indicating this region became
highly disordered upon acylation of cefotaxime
(Figure 3b). Based on these observations we did not
include fluorescein molecule or the disordered region of
Ω-loop in our final refined structure of PenP-E166Cf-
cefotaxime.
The overall structure folding of fluorescein-labeled
and cefotaxime-bound PenP is nearly identical to that of
the wild-type unlabeled PenP and the fluorescein-labeled
PenP-E166Cf. From the calculation result by the CCP4
program, it was found that the B factor of Glu163,
(c)
?-loop
GC1
Toho-1
PenP-E166Cf
Ser70
cefotaxime
Ω-loop
Cys166
Ser70
cefotaxime
fluorescein
?-loop
(a) (b)
(c)
Figure 3 Crystal structure of PenP-E166Cf-cefotaxime. (a) The fo-fc map of cefotaxime in PenP-E166Cf-cefotaxime complex contoured at 2.0
s. The light blue dash line represents the disordered Arg164 to Pro174 due to the poor electron density. (b) Comparison of PenP-E166Cf-
cefotaxime complex with apo PenP-E166Cf structure. The two structures are superimposed by main chain atoms. Key residues including Cys166,
Ser70 and cefotaxime are also shown in cpk cylinder model. (c) Comparison of binding mode of cefotaxime in PenP-E166Cf with that of Toho-1
and GC-1. PenP-E166Cf, Toho-1 and GC1 are superimposed by aligning on overall main chain atoms. Cefotaxime is in cylinder model colored in
cpk (PenP-E166Cf-cefotaxime), golden (Toho-1) and red (GC1) respectively.
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Gly175, Glu176 on Ω-loop, which are next to the disor-
dered region, is significantly higher (~65 Å2) than other
parts of the protein (~20 Å2). The refinement statistic
for this set of crystal structure has different values from
that of the apo PenP-E166Cf structure due to the cefo-
taxime and the difference in Ω-loop.
To investigate why the binding and acylation of cefotax-
ime causes the Ω-loop and the conjugated fluorescein
molecule to become highly flexible and structural disor-
dered, we superposed the PenP-E166Cf structure onto the
PenP-E166Cf-cefotaxime complex structure. Fluorescein is
seen as occupying a site that partially overlaps with the
acylated cefotaxime; particularly the benzoic group of
fluorescein molecule is in direct steric clash with the
7-amino substituent of cefotaxime (Figure 3b). Thus the
binding and acylation of cefotaxime to PenP would dis-
place fluorescein from its original position to avoid steric
clash. It is likely that the Ω-loop, in order to accommodate
such displacement, loses its well-folded structure and
becomes highly flexible. As a consequence the fluorescein
molecule conjugated to the flexible Ω-loop becomes fully
exposed to the polar aqueous environment, leading to
enhanced fluorescence. Thus our structural findings con-
firmed our initial proposal of a biosensing mechanism
based on displacement of fluorescein [15,16].
To understand the impact of conjugated fluorescein
molecule on the substrate binding kinetics of PenP we
compared the PenP-E166Cf-cefotaxime structure to two
other β-lactamase structures in complex with cefotaxime,
including the narrow-spectrum Toho-1 and the
extended-spectrum GC1 [19,20]. In Toho-1 structure the
methoxyimino side chain points away from the active site
and is solvent-exposed (Figure 3c). Such an orientation
packs the methoxyimino side chain tightly against the
thiozolyl ring, leading to a distorted configuration of the
cephem nucleus that is catalytically incompetent for dea-
cylation [19]. In GC1 structure the transition analog of
cefotaxime binds to GC1 in a fully extended conforma-
tion, with oxyimino group inserted to active site and
extended away from the thiozolyl ring (Figure 3c). This
conformation is regarded as catalytically competent to
facilitate deacylation because the distortion on the
cephem nucleus is released [20]. Importantly, the binding
mode of cefotaxime in our PenP-E166Cf-cefotaxime
structure closely resembles that of GC1 (Figure 3c), sug-
gesting that with its Ω-loop fully flexible the naturally
narrow-spectrum PenP can accommodate cefotaxime in
a manner that resembles the extended-spectrum GC1.
Conclusions
Our structural studies indicate the molecular mechan-
ism how fluorescein-labeled β-lactamase detects β-lac-
tam antibiotics. The conjugated fluorescein molecule is
located near the catalytic site and partially occupies the
antibiotic binding region. The binding and acylation of
β-lactam antibiotics such as cefotaxime would expel the
fluorescein molecule from its original position and leads
to increased flexibility of the Ω-loop, to which the fluor-
ophore is linked. As a result, the fluorophore is relo-
cated from its original position with partial solvent
exposure to become fully solvent exposed, leading to
enhanced fluorescence emission. These findings confirm
our previous proposal based on structural modeling.
Furthermore the Ω-loop demonstrates the propensity
of becoming highly flexible and unstructured if its tight
packing against the catalytic site is disturbed. Such
increased flexibility enables PenP to bind and acylate
cefotaxime, a naturally poor substrate, in a manner that
resembles the extended-spectrum cefotaxime-resistant
β-lactamases. This finding could be valuable in the
future design of novel antibiotics that resist the binding
or hydrolysis by β-lactamases.
Methods
Protein expression and purification
Two constructs of PenP protein were used for our
experiments, the maltose binding protein (MBP)-fusion
construct for time-dependent fluorescence measure-
ments and the His6-tagged construct for crystallization
and structural studies, as well as scanning fluorescence
spectra. The MBP fusion has been shown not to inter-
fere with fluorescence measurements in our previous
studies (data not shown). The MBP-fusion construct
was cloned into pMAL-c2X vector (NEB). The His6-
tagged PenP enzyme was cloned into a modified pRset-
A vector (Invitrogen) with a TEV protease cleavage site
upstream of the PenP gene. The E166C mutation was
constructed using QuikChange Site-Directed Mutagen-
esis Kits (Strategene).
The MBP-fusion construct was expressed in E. coli
strain BL21 (DE3) at 37°C for overnight after induction
by 300 μM IPTG when A600 reached 0.5-0.7. The har-
vested cells were centrifuged and lysed by sonication.
The supernatant after sonication was passed through
amylose affinity chromatography. The eluted fractions
were pooled and buffer exchanged to 20 mM ammo-
nium bicarbonate. The protein was freeze-dried for sto-
rage afterwards.
The His6-tagged PenP protein was expressed in E. coli
strain BL21 (DE3) at 37°C for overnight after induction
by 200 μM IPTG when A600 reached 0.8-1.2. The har-
vested cells were centrifuged and the supernatant was
passed through Nickel affinity chromatography, followed
by DEAE anion exchange chromatography. The frac-
tions containing the target protein were pooled and con-
centrated by Amicon® Ultra-15 Centrifugal Filter
Devices (Millipore NMWL = 10,000). The His6-tag was
cleaved by adding the TEV protease in 1:20 molar ratio
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to the concentrated PenP-E166C protein (2 mg/ml). The
mixture was incubated at 30°C for 6 hours and was
further purified by Nickel affinity chromatography to
remove uncleaved protein.
Fluorescein labeling of PenP-E166C to form PenP-E166Cf
A ten-fold molar excess of fluorescein, with concentra-
tion of 20 mM, was dissolved in DMF (Dimethyl forma-
mide) and added to the concentrated PenP-E166C
protein solution drop by drop. The labelling reaction
was allowed to proceed in darkness with stirring for
1 hour, and then dialysed against 50 mM potassium phos-
phate buffer (pH 7.0) at 4°C for several times in order to
remove excess fluorescein. The labelled PenP-E166Cf pro-
tein was concentrated to less than 1 ml and further puri-
fied by Superdex™ 75 gel filtration column (GE
Healthcare). The running buffer contains 20 mM Tris-
HCl, 50 mM NaCl, pH 7.5. The target fractions were
pooled and concentrated by Amicon Ultra to 25 mg/ml.
The labelling efficiency was confirmed by ESI-MS.
Fluorescence spectra of PenP-E166Cf for antibiotic
detection
Fluorescence profile of PenP-E166Cf alone, as well as in
presence of various β-lactams were measured using Per-
kin-Elmer LS50B spectrofluorimeter. Both scanning
spectra and time-dependent spectra were measured. Dif-
ferent β-lactam antibiotics, including cefotaxime, cef-
triaxone, ceftazidime, cephaloridine, cephalothin,
cefoxitin, cefuroxime, penicillin G, and ampicillin, were
incubated with PenP-E166Cf for 100 s at 1 μM to allow
sufficient acylation of the antibiotic to form ES* adduct.
The product after acylation was subjected to fluores-
cence measurement as previously described [15].
Crystallization, structure determination and refinement
Crystals of PenP-E166Cf were grown by hanging-drop
vapour diffusion method after mixing 1 μl of protein
and 1 μl of reservoir solution containing 25% (w/v) PEG
4000, 0.1 M Hepes pH 7.2, 0.4 M NH4Acetate and 0.2
M K2HPO4. Small crystals in the form of clustered nee-
dles appeared readily. For data collection, single crystals
were obtained after separating them from the clustered
needles. Crystals were harvested and cryoprotected in its
reservoir solution supplemented with 20% ethylene gly-
col for one minute prior to flash freeze and data collec-
tion on the Rigaku MicroMax™-007HF x-ray machine.
For PenP-E166Cf-cefotaxime data set, crystals were
soaked in its growth solution added with 0.01 M of
cefotaxime for 15 minutes and then mounted to the
x-ray machine. Data were integrated and scaled by Crys-
talClear™1.3.5 SP2 (Rigaku Inc.).
The crystals belong to the monoclinic group P21 with
cell parameter: a = 43.43 Å, b = 92.3 Å, c = 66.43 Å and
β = 104°. The PenP-E166Cf crystals diffracted to 2.15 Å
resolution, while the PenP-E166Cf-cefotaxime crystal
diffracted to 2.8 Å. Both structures were determined by
molecular replacement using PenP structure as the
search model (PDB ID 4BLM) [21]. The program
COOT was used for inspection of electron density maps
and model building [22]. There are two molecules per
asymmetric unit. The fluorescein and cefotaxime mole-
cules were built by PRODRG [23] and appended to the
PenP structure for refinement. Structure determination
and refinement of PenP-E166Cf and PenP-E166Cf-
cefotaxime were done using the CCP4 program suite
[18]. A summary of the crystallographic data and refine-
ment statistics are given in Table 1. The coordinates
and structure factors from this study have been
Table 1 X-ray data-collection and structure refinement
statistics.
E166Cf E166Cf+cefotaxime
PDB code 3M2J 3M2K
Data collection
Space group P21 P21
Unit cell parameters (Å)
a 43.3 43.5
b 92.3 91.4
c 66.3 66.1
b 104.82 104.52
Resolution range (Å) 52-2.15
(2.24-2.15)
45-2.80
(2.95-2.80)
No. of total reflections 79750 40611
No. of unique reflections 29537 12412
I/s 7.1 (2.7) 6.3 (2.4)
Completeness (%) 97.0 (99.5) 99.8 (99.9)
Rmerge (%) 9.7 (27.1) 11.8 (32.0)
Structure refinement
Resolution (Å) 50.0-2.20 45.0-2.80
Rcryst/Rfree (%) 20.0/23.2 21.2/27.7
r.m.s.d. bonds (Å)/angles (°) 0.018/1.784 0.010/1.672
No. of reflections
Working set 24217 11749
Test set 1291 647
No. of atoms
Protein atoms 4011 3706
Water molecules 254 29
Average B-factor (Å2)
Main chain 24.7 16.96
Ligand molecules 48.4 42.46
Water 32.7 10.7
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deposited into Protein Data Bank (PDB) under accession
codes 3M2J (PenP-E166Cf apo structure) and 3M2K
(PenP-E166Cf-cefotaxime).
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